Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the severity of coronavirus disease 2019 (COVID-19).
Objectives: We aimed to understand if MS DMTs are associated with differences in COVID-19 prevention behaviors or rate of PCR testing as a possible result of safety perceptions. Assessing such association is important for counseling MS patients.
Methods: We analyzed COVID-19 surveys sent to patients at 2 sites from the MS Partners Advancing Technology and Health Solutions (MS PATHS) network. COVID-19 prevention behaviors were assessed via questions on social distancing, mask wearing, hand hygiene, group gatherings, as well as DMT changes due to COVID-19 and frequency of PCR testing. Descriptive analysis was conducted among responders based on their self-reported current DMT.
Results: Among the initial 653 survey responders, mean (SD) age was 52.9 (11.8) years; patients on interferons (IFNs) and glatiramer acetate (GA), n=65 combined, were on average older (56.5 yrs) than patients on natalizumab (NAT, n=53) 45.7 yrs, B-cell therapies (n=203) – 50.0 yrs, and oral DMTs (n=165) – 50.6 yrs. A delay in DMT dosing was reported for 7 (3.4%) patients on B-cell DMTs vs. none for other DMTs. Self-isolation was reported by 40% of NAT patients vs approximately 60% of patients on IFN/GA, B-cell and oral DMTs. Over 90% of responders across DMTs stated keeping a 6-feet distance in public and over 80% reported wearing a mask. Hygiene recommendations were followed similarly across DMTs. The proportion of patients on high efficacy DMTs (B-cell therapies and NAT) who were PCR-tested trended higher than in patients on oral DMTs and IFN/GA 13.3%, 8.5%, 7.7%, respectively (Fishers p=0.08 for high efficacy DMTs vs oral/IFN/GA). Data from follow up surveys asking about COVID-19-related perceptions of DMTs and including a larger sample will be presented.
Conclusions: Initial survey results in an MS population suggest that patients on higher efficacy DMTs might be more likely to be tested for COVID-19 than those on IFN/GA or oral DMTs. Planned analyses of follow up survey data may reveal evolving differences in COVID-19 prevention behaviors and DMT safety perceptions over the course of the pandemic. A better understanding of the potential impact of DMTs on patient behaviors or COVID testing frequency is important for optimal counseling and for designing comparative studies across DMTs.
Please login to see your profile content